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The transcription factor Fos is involved in cell proliferation and differentiation. Its expression in normal and 
pathological adult human tissues and cells has rarely been studied. We therefore studied bronchial biopsies 
obtained from 14 normal subjects (NS), 18 non-steroid-treated asthmatics, 10 corticosteroid-treated asthmat- 
ics and 10 patients with chronic bronchitis (CB), in addition to 34 patients with lung cancer (LC), by 
immunofluorescence for Fos immunoreactivity, using a highly specific polyclonal antibody. Bronchial tissue of 
O/l0 NS, 1 l/l8 non-steroid-treated asthmatics, l/l0 steroid-treated asthmatics, 0110 CB and l/34 LC expressed 
Fos. In asthmatic patients, the expression was heterogeneous, localized to epithelial cells and correlated with 
the epithelium shedding (~=0.45, P=O.OOOl). Corticosteroid-treated patients rarely expressed Fos, suggesting 
a role for this proto-oncogene in asthmatic bronchial inflammation. Fos was rarely expressed in the normal 
and pathological (CB, LC) proliferative compartment of the human bronchi, suggesting its low role in cell 
proliferation of the large airways. 
Introduction 
C-fos proto-oncogene codes for a transcription 
factor and is a member of the Fos family, including 
c-fos, Fra-1, Fra-2, Fos-B and ~Fos-B (1,2). It 
belongs to the group of immediate early genes, 
rapidly and transiently induced by a wide variety of 
stimuli. It appears to play a major role in cell 
proliferation and differentiation. It is a highly regu- 
lated gene, with multiple negative regulatory loops 
(1,2). Its expression in normal adult human tissues 
and cells has rarely been studied. Apart from circu- 
lating neutrophilic granulocytes (3,4) and skin (5), it 
is not or faintly detectable. In human extrapulmon- 
ary diseases, Fos has been reported to be markedly 
decreased in premalignant and malignant tissues 
from patients with familial polyposis coli (6) and in 
psoriasis (7) although it is intensively expressed in 
osteosarcoma and synovium of rheumatoid arthritis 
patients (8,9). Volm et al. have reported the presence 
of Fos protein in more than 40% of the squamous cell 
carcinomas of the lung (10). We have recently studied 
the expression of Fos protein in human normal and 
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asthmatic bronchi obtained by fiberoptic broncho- 
scopy (11). Using the immunofluorescence technique 
with a highly specific polyclonal antibody, we showed 
that Fos was present in eight out of 12 untreated 
asthmatic subjects but not in 10 normal controls. 
This expression was in general observed on epithelial 
cells in areas where there was discernible epithelial 
shedding, one of the important pathological charac- 
teristics of bronchial asthma (11). Moreover, the 
proliferating cell nuclear antigen was rarely expressed 
indicating that the epithelium in asthmatics is not 
hyperproliferative. We thus hypothesized that Fos is 
not related to epithelial proliferation and may rather 
reflect activation (via the inflammatory micro- 
environment) than proliferation of the bronchial 
epithelium in asthma. The increased expression of 
Fos protein(s) in asthma may explain, at least in part, 
the efficacy of corticosteroids in this disease since 
there is a negative interaction between c-fos protein 
and the glucocorticosteroid receptor (12). Consider- 
ing the beneficial role of corticosteroids (13) in 
asthma and their dual relationship with Fos proteins 
(12), it is important to study Fos bronchial expres- 
sion in corticosteroid-treated asthmatics. Moreover, 
proliferative diseases of the bronchi, such as chronic 
bronchitis (CB), have never been tested. 
Here, we extended our study on Fos protein 
expression in the human large airways using 
:cil 1995 W. B. Saunders Company Ltd 
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Table I Characteristics of the asthmatic patients and immunostaining results 
Fos staining* 
Subjects Aas Smoking FEV, Epithelium Intensity 
(n=28) Sex/Age score Allergy* (pack years) (% predicted) Treatment shedding Distribution 
Non-steroid-treated patients (n= 18) 
1 M/35 1 Poly 
2 F/51 1 No 
3 M/24 1 Poly 
4 M/31 1 Poly 
5 Ml56 1 Poly 
6 Ml50 2 Mono 
7 M/61 2 No 
8 F/21 2 Poly 
9 M/17 2 Poly 
10 F/48 2 No 
11 F167 2 No 
12 M/18 2 Poly 
13 Ml30 3 Poly 
14 M/19 3 No 
15 Ml32 3 Poly 
16 F/34 4 NO 
17 Fl67 4 No 
18 Ml27 4 Poly 
Corticosteroid-treated patients (n= 10) 
19 Ml56 2 Poly 
20 F/69 2 No 
21 Ml67 2 No 
22 Ml39 4 No 
23 Ml47 4 No 
24 Fl36 4 Mono 
25 Ml73 5 No 
26 F/55 5 No 
27 F/42 5 No 
28 Ml36 5 Poly 
0 100 
0 74 
0 66 
0 95 
10, current 100 
30, current 99 
10, current 83 
0 91 
0 81 
0 110 
0 70 
0 68 
2, current 95 
0 63 
0 70 
0 84 
0 69 
0 50 
0 80 
0 120 
0 98 
0 90 
0 72 
0 74 
0 100 
0 71 
0 80 
30, previous 50 
2 
3 
2 
2 
2 
0 
0 
0 
0 
0 
2 
+ B 
++ B 
++ B 
0 
++ B 
0 
0 
++ B 
0 
+ B, MN 
+ B 
0 
++ B 
+++ B 
++ B 
0 
+++ B 
0 
0 
0 
0 
0 
0 
f 
0 
0 
0 
0 
*Abbreviations: + + +, very strong staining; + +, moderate staining; +, faint staining; & , very faint staining; 0, no staining; 
B, positive epithelial cells; & &agonists; CS, corticosteroids; MN, very few positive basal mononuclear cells in the 
submucosa; Mono, monosensitization; Poly, polysensitization; M, male; F, female. 
tshedding graded as 0:>80% of the basal membrane covered with epithelial cells; 1,60-80%; 2,3&60%; and 3, ~30% of the 
basal membrane covered with epithelial cells. 
immunohistochemistry in fiberoptically obtained 
bronchial biopsies from 14 normal subjects (NS), 18 
untreated or non-steroid-treated asthmatics, 10 
steroid-treated asthmatics and 10 patients with CB. 
Thirty-four patients with lung cancer (LC) were also 
studied. 
Materials and Methods 
SUBJECTS 
Fourteen healthy subjects (18-44 years, 30 * 9 
years) were used as a control group: nine of whom 
were lifelong non-smokers and five healthy smokers. 
The pulmonary function was within normal range, 
they were non-allergic and had never suffered from 
asthma nor chronic bronchitis. None of them were 
receiving any treatment. No subject had suffered 
from any respiratory tract infection during the month 
preceding the test. 
Twenty-eight asthmatics were studied (Table 1). 
Asthma was defined as previously (14), according to 
the criteria of the American Thoracic Society (15), 
and the severity assessed by the clinical score of Aas 
(16). Immediate type hypersensitivity was confirmed 
by positive skin-prick tests with common aeroaller- 
gens and serum allergen-specific IgE (Phadebas 
RAST’% , Pharmacia Diagnostics AB, Uppsala, 
Sweden). Five subjects were smokers and no subject 
had any respiratory tract infection or an acute 
exacerbation during the month preceding the test. 
Ten patients (36-73 years, 52 f 14 years) were being 
treated with corticosteroids: eight with inhaled 
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beclomethasone (100%2OOOpg day ~ ‘) and two with 
inhaled budesonide (1200 ug day ~ ‘). All of these 
patients have received daily inhaled corticosteroids 
over the past 6 months, and the cumulative dose was 
over 2 mg for this period of time. Eighteen patients 
(17-67 years, 38 f 17 years) had never received any 
corticosteroid. &agonists were stopped 8 hr prior to 
the study. 
Ten patients with CB (35-68 years, 51 f 12 years) 
were studied. Chronic bronchitis was defined 
according to the criteria of the American Thoracic 
Society (15), and all patients had cough and sputum 
production on most days for at least 6 months 
year - ’ during the previous 2 years, without any 
significant reversible airways obstruction. Patients 
were excluded if they showed a history of allergic 
diseases, wheezing, an improvement of FEV, of more 
than 10% after inhalation of 2OOpg of salbutamol, 
and if they had had a bronchial infection the month 
preceding the study. They were all smokers and did 
not receive any treatment. 
Thirty-four patients (4681 years, 61 & 9 years) 
with histologically-proven primary LC were also 
studied (14 squamous cell carcinoma, 10 adeno- 
carcinoma and 10 small cell carcinoma). They were 
classified according to the new international staging 
system and the American Thoracic Society map of 
regional pulmonary nodes, as previously described 
(17). No patient had received any chemical or physi- 
cal treatment for their cancer. They were all smokers 
and suffered from CB. 
The study was performed after informed consent 
was obtained and approval of the Ethics Committee 
of the Hospital was given. 
PATHOLOGICAL EXAMINATION OF BRONCHIAL MUCOSA 
Non-small cell lung carcinoma (NSCLC) samples 
were obtained after complete surgical resection of the 
primary tumour. All other samples were biopsies 
recovered by fiberoptic bronchoscopy performed as 
previously described (14) using alligator forceps in 
sub-segmental bronchi. 
The biopsies were fixed in 3.7% w/v formalde- 
hyde and embedded in paraffin blocks. Sections of 
2,um were deparaffined, rehydrated and then per- 
meabilized in methanolacetone before immuno- 
histochemistry. A first section was stained with 
haematoxylin and eosin (H&E) for routine histologic 
evaluation. 
The slides were incubated with a highly-specific 
rabbit anti-human Fos antiserum (final dilution 1: 
100) and a mouse anti-human cytokeratin (Dako, 
Glostrup, Denmark) for 1 h at 37°C in humid cham- 
bers. The anti-human Fos antiserum was obtained by 
immunization of a rabbit with a fusion protein 
b-Gal/c-j& (amino acids 150-293 of the protein 
C-$X). The epitope recognized by the Fos antibody is 
from the common region of the protein, present in all 
members of the Fos family and therefore does not 
differentiate between each of them. The specificity of 
the antibody had been demonstrated by western 
blotting (18,19). Sections were washed three times 
in PBYBSA (10 min each) and then incubated 
for 30 min with a donkey biotinylated anti-rabbit 
IgG (final dilution 1:lOO) (Boehringer Mannheim, 
Meylan, France) and a fluorescein isothiocyanate 
(FITC) conjugated goat anti-mouse antibody (final 
dilution 1:SO) (Boehringer Mannheim). Sections were 
again washed three times and then incubated with 
the streptavidin-Texas Red (final dilution 1:lOO) 
(Boehringer Mannheim). Control slides were pre- 
pared by using an irrelevant antibody of the same 
isotype at the same concentration as the specific 
primary monoclonal antibody (Dako). A431 cells 
were serum-starved overnight, and stimulated with 
serum and used as positive control for the Fos 
antiserum (5). 
Two different investigators, both unaware of the 
clinical findings, examined the slides. Fos immuno- 
staining intensity was graded semi-quantitatively as 
follows: + + +, very strong staining; + +, moderate 
staining; +, faint staining; f very faint staining, 
or-no staining. Epithelial shedding, one of the impor- 
tant feature of asthmatic biopsies, was examined on 
areas where no evident traumatic artifact (i.e. away 
from the edges of the biopsies) were observed, and 
graded as previously described: 0, over 80% of the 
basal membrane covered with epithelial cells; 1, 
6%80%; 2, 30-60%; and 3, less than 30% (11). For 
cancer samples, non necrotic areas were analysed. 
STATISTICAL ANALYSIS 
The Kruskal-Wallis and Mann-Whitney U-tests 
were used for statistical comparisons between the 
groups. Correlations were assessed by Kendall’s 
r-test. Bonferroni’s correction was used to analyse 
the statistical tests. Results are given as means & 
standard deviations (SD). 
Results 
PATIENT CHARACTERISTICS 
Fifteen patients had mild asthma (Aas scores l-2), 
three moderately severe asthma (Aas score 3) and 10 
severe asthma (Aas scores 4-5) (Table 1). As 
expected, in terms of Aas score, patients treated with 
steroids had a more severe disease (3.8 5 1.3) than 
non-steroid-treated asthmatics (2.0 & 1.1) (P=O.OOS). 
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They were older (52 f 14 years) than NS (30 & 9 
years, PcO.01) and non-steroid-treated asthmatics 
(38 & 17 years, P=O.O25). Fourteen patients were 
allergic. There was no difference in the daily dose of 
P-agonists. 
Patients with CB were significantly older than NS 
(51 & 12 years, P<O.Ol). FEV, ranged from 40-l 18% 
of predicted values (83 * 29%). Patients with LC 
shared similar characteristics with the group with 
chronic bronchitis, in terms of FEV,, sex age and 
tobacco history (data not shown). 
PATHOLOGICAL EXAMINATION OF THE BIOPSIES USING 
HAEMATOXYLIN AND EOSIN STAINING 
H&E staining of the biopsies of asthmatic patients 
revealed an increased thickness of the basement 
membrane, and a partial shedding of the epithelium 
in 22/28 samples. Corticosteroid-treated asthmatics 
had significantly less epithelium shedding than non- 
steroid-treated asthmatics (P=O.O0006). An increase 
in the number of inflammatory cells (eosinophils and 
mononuclear cells) was observed in all the biopsies 
obtained from asthmatics. Biopsies from CB showed 
an increased thickness of the basement membrane in 
3/10 patients, a partial shedding of the epithelium in 
7/10 patients (mostly grade 1), and very often mucous 
hyperplasia. Squamous cell dysplasia, with or with- 
out nuclear atypia, was observed in 7110 patients. LC 
showed various degrees of differentiation (data not 
shown). 
IMMUNOHISTOCHEMISTRY 
There was good agreement between the two 
observers for Fos immunofluorescence analysis. 
There was no staining observed in the control sec- 
tions in which unrelated rabbit antisera was used as 
the primary antibody. Fos staining was seen in 
bronchial epithelial cells of 1 l/l 8 non-steroid-treated 
asthmatics and no Fos expression was observed in 
normal subjects, corticosteroid-treated asthmatics 
and CB [Plate 1 (a-d)]. One LC was positive (scat- 
tered immunostaining). The staining was localized to 
the nucleus of the cell with only very low background 
staining in the cytoplasm. The expression of Fos was 
very bright (+ + +) in two patients, moderate (+ +) in 
six patients and faint (+) in the three remaining 
patients. One corticosteroid-treated asthmatic 
showed a very faint staining. In all but one patient, 
only cells positive for anti-cytokeratin antibody were 
stained for Fos. However, even in this case, the 
localization and the morphology of the cells indicated 
that they were of epithelial origin and certainly basal 
epithelial cells. In one asthmatic patient, some mono- 
nuclear cells of the submucosa were also stained for 
I I I I 
0 1 2 3 
Epithelium shedding 
Fig. I Correlation between Fos staining and the grade of 
epithelium shedding of lung tissue of 18 non-steroid-treated 
asthmatics (0) and 10 steroid treated-asthmatics (-j), 
obtained by endobronchial biopsy (r=0.45, P=O.OOOl). 
Fos. In general, Fos-positive cells were only observed 
in areas where there was discernible epithelial 
shedding. Moreover, in the Fos-negative biopsies of 
non-steroid-treated asthmatics and in corticosteroid- 
treated asthmatics the shedding of the epithelium was 
moderate and there was a statistical correlation 
between the grade given for Fos and that of the 
epithelial shedding (~=0.45, P=O.OOOl, Kendall test) 
(Fig. 1). There was no correlation between Fos 
staining or the epithelium shedding and the atopy 
status nor the severity of asthma assessed by the 
clinical score of Aas or FEV,. There was no epi- 
thelium shedding in bronchial biopsies from normal 
subjects. 
Discussion 
This study shows that Fos is highly-expressed 
in the bronchial epithelium of non-steroid-treated 
asthmatics, and that this expression is no longer 
present when asthmatics are treated with corticoster- 
oids. On the other hand, Fos is not expressed in 
chronic bronchitis and lung cancer. 
The specificity of the anti-Fos antibody we used 
has previously been demonstrated (18,19). Since it is 
directed against a common epitope of the five mem- 
bers of the Fos family, the results in the present study 
do not indicate a role for c-fos itself in asthma, but of 
one of the Fos proteins. 
In asthma, we extended our previous study by 
increasing the number of non-steroid-treated patients 
and by adding corticosteroid-treated patients. We 
could confirm that Fos immunoreactivity is present 
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in the respiratory epithelium of at least 60% of 
non-steroid-treated asthmatics. The positive cells 
were pancytokeratin-positive, usually non-ciliated, 
probably basal epithelial cells, although we did not 
use antibodies specific for these cells. The fact that 
this positivity was often present in shed areas of the 
epithelium seems to indicate that Fos could play a 
role in the asthmatic inflammation. This gene may be 
activated by the inflammatory mediators involved in 
asthma such as histamine (20) or platelet-activating 
factor (21). Glucocorticosteroids are the main treat- 
ment for the asthmatic inflammation (13). Their 
mechanisms(s) of action is (are) not clearly defined 
(22). The mutual negative interference between AP-1 
(composed of two subunits; Fos and Jun) (1,2) and 
glucocorticosteroid receptor (GR) may be one of two 
mechanisms (13,23). It could either be a mutually- 
exclusive binding to DNA (overlapping &acting 
elements), or a protein-protein negative interaction 
that results in mutual loss of DNA-binding activity 
(12). As a novel approach to studying the modulation 
of the polarized epithelial phenotype, Reichmann 
et al. (24) have expressed c-Fosloestrogen receptor 
fusion proteins in mammary epithelial cells. Short- 
term activation of c-Fos induced the reversible loss 
of morphological and functional cell polarity. In 
contrast, long-term stimulation of c-Fos caused the 
cells to depolarize irreversibly, suggesting that Fos 
proteins may modulate the attachment of epithelial 
cells and might be involved in the disruption of the 
epithelial structure. In our study, the corticosteroid- 
treated asthmatics did not have any Fos im- 
munoreactivity within their bronchial epithelium. 
Glucocorticosteroids could either switch off genes 
involved in the asthmatic bronchial inflammation, 
which are known to activate Fos genes, and/or 
directly block Fos expression. These actions may 
then promote the reparation process leading to the 
re-epitheliazation, since the epithelium is shed less in 
corticosteroid-treated asthmatics than in non-steroid- 
treated asthmatics. However, the role of Fos proteins 
in his reparation can not be determined here, since 
glucocorticosteroids could directly switch on genes 
involved in this reparation. Many steps in this 
process are still unclear. 
Chronic bronchitis and lung cancers are proliferat- 
ive diseases. This study suggests that Fos does not 
appear to be involved in these premalignant and 
malignant processes, confirming our hypothesis that 
this proto-oncogene is not directly related with 
human bronchial proliferation. Fos is rarely involved 
in spontaneous tumours, contrary to other proto- 
oncogenes like myc or ras (25). This is probably due 
to the existence of negative regulatory loops present 
at almost all steps governing its expression (25). 
Interestingly, the two mouse osteosarcoma retro- 
viruses FBJ-MSV (Finkel-Biskis-Jinkins) and FBR- 
MSV (Finkel-Biskis-Reilley) containing v-fos, have 
eliminated most of these negative regulatory elements 
and thus, by overproducing the protein, can give rise 
to cell transformation (25). Osteosarcoma is the most 
documented human cancer involving C-$X (9). In 
lung cancer, Volm et al. (10) reported the presence of 
c-fos protein in more than 40% of the squamous cell 
carcinomas of the lung, which is in contradistinction 
with our data. In their study, the patients appear to 
be quite similar to ours, the way the biopsies were 
processed is not explained and the Fos antibody is 
different, directed against the human C--OS amino- 
acids 417. However, two recent studies in human 
lung non-small cell (SK-Lu-1, SK-MES-1, A427, 
A549) and small cell (Lu134BS) carcinoma cell lines 
did not show any increase in c-fos mRNA (26,27). 
Inflammation is obviously present not only in chronic 
bronchitis but also in lung cancer, as shown at least 
by the mononuclear cell infiltrate in the biopsies. In 
our study, it turns out that this inflammation does 
not imply Fos proteins as it does in asthma, even 
when an epithelium shedding (always moderate in 
this study) is present. Thus, Fos proteins in the 
human large airways are not expressed in the pro- 
liferative compartment, nor in a proliferative status 
(dysplasia, neoplasia). However, their role in the 
asthmatic bronchial inflammation needs to be 
confirmed. 
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